natgillin/translations-raw huggingface dataset:
For more information on generic and hybrid medicines, see the questionand-answer document here.
Za več informacij o generičnih in hibridnih zdravilih si oglejte dokument z vprašanji in odgovori, ki je na voljo tukaj.
The European Commission granted a marketing authorisation valid throughout the European Union for Capecitabine Medac on 19 November 2012.
Evropska komisija je dovoljenje za promet z zdravilom Capecitabine Medac, veljavno po vsej Evropski uniji, odobrila dne 19. novembra 2012.
Pyrimidine is part of the genetic material of cells (DNA and RNA).
Pirimidin je del genskega materiala celic (DNK in RNK).
Doses need to be adjusted for patients with liver or kidney disease and for patients who develop certain side effects.
Odmerke je treba prilagoditi za bolnike z obolenji jeter ali ledvic in za bolnike, pri katerih se pojavijo določeni neželeni učinki.
It is available as tablets (150, 300 and 500 mg).
Na voljo je v obliki tablet (150, 300 in 500 mg).
The full EPAR for Capecitabine Medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Capecitabine Medac je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For other types of cancer, treatment is stopped if the disease gets worse or the patient cannot tolerate the treatment.
Pri drugih oblikah raka se zdravljenje prekine, če bolezen napreduje ali če bolnik zdravljenja ne prenaša.
Capecitabine Medac tablets should be swallowed with water within 30 minutes after a meal.
Tablete zdravila Capecitabine Medac je treba pogoltniti z vodo v 30 minutah po obroku.
It is taken as tablets, while 5-FU normally needs to be injected.
Jemlje se v obliki tablet, medtem ko je treba 5-FU navadno injicirati.
This means that it is similar to a ‘reference medicine', but it contains capecitabine at a new strength in addition to existing strengths.
To pomeni, da je podobno „referenčnemu zdravilu“, vendar je poleg že obstoječih jakosti na voljo tudi v novi jakosti.
Treatment is continued for six months after colon surgery.
Zdravljenje traja šest mesecev po operaciji debelega črevesa.
The doctor will calculate the number of 150, 300 and 500 mg tablets the patient needs to take.
Zdravnik bo izračunal število 150-, 300- in 500-miligramskih tablet, ki jih mora bolnik vzeti.
This is a summary of the European public assessment report (EPAR) for Capecitabine Medac.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Capecitabine Medac.
The company provided data from the published literature on capecitabine.
Družba je predstavila podatke o kapecitabinu iz objavljene literature.
Because Capecitabine Medac contains the same active substance as its reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker zdravilo Capecitabine Medac vsebuje isto zdravilno učinkovino kot referenčno zdravilo, se šteje, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
For more information about treatment with Capecitabine Medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Capecitabine Medac preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Capecitabine Medac is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient's height and weight).
Jemlje se dvakrat na dan v odmerkih med 625 in 1 250 mg na kvadratni meter telesne površine (izračunane na podlagi bolnikove višine in telesne mase).
The dose depends on the type of cancer being treated.
Odmerek je odvisen od vrste raka, ki se zdravi.
The full EPAR for the reference medicine can also be found on the Agency's website.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za referenčno zdravilo je prav tako na voljo na spletni strani agencije.
What are the benefits and risks of Capecitabine Medac?
Kakšne so koristi in tveganja, povezani z zdravilom Capecitabine Medac?
Capecitabine is a ‘prodrug' that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Kapecitabin je „predzdravilo“, ki se v telesu pretvori v 5-florouracil (5-FU), in sicer v večji meri v tumorskih celicah kot v normalnem tkivu.
The CHMP concluded that, in accordance with EU requirements, Capecitabine Medac has been shown to have comparable quality and to be bioequivalent to Xeloda.
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Capecitabine Medac primerljivo raven kakovosti kot zdravilo Xeloda ter da mu je biološko enakovredno.
In the body, 5-FU takes the place of pyrimidine and interferes with the enzymes involved in making new DNA.
5-FU v telesu zavzame mesto pirimidina in ovira encime, ki sodelujejo pri tvorjenju nove DNK.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Capecitabine Medac.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Capecitabine Medac, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
• locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
• lokalno napredovalega ali metastatskega raka dojk (raka dojk, ki se je začel širiti na druge dele telesa).
Full details are available in the summary of product characteristics (also part of the EPAR).
Za podrobnejše informacije glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
It can also be used on its own when treatment with both anthracyclines and taxanes (another type of anticancer medicine) has failed or when repeat treatment with anthracyclines is not suitable for the patient.
Lahko se uporablja tudi kot samostojno zdravilo, če je bilo zdravljenje z antraciklini in taksani (drugima vrstama zdravil proti raku) neuspešno ali če ponovno zdravljenje z antraciklini za bolnika ni primerno.
• metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
• metastatskega kolorektalnega raka (raka debelega črevesa, ki se je razširil na druge dele telesa).
While the reference medicine, Xeloda, is available as 150 and 500 mg tablets, Capecitabine Accord is also available as 300 mg tablets.
Referenčno zdravilo Xeloda je na voljo v obliki 150- in 500-miligramskih tablet, zdravilo Capecitabine Medac pa je na voljo tudi v obliki 300-miligramskih tablet.
Other information about Capecitabine Medac
Druge informacije o zdravilu Capecitabine Medac
Therefore, the CHMP's view was that, as for Xeloda, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi, tako kot pri zdravilu Xeloda, odtehtajo znana tveganja.
• colon (large bowel) cancer.
• raka kolona (debelega črevesa).
The company carried out a ‘bioequivalence' study to show that 500 mg Capecitabine Medac produces the same levels of capecitabine in the blood as 500 mg Xeloda.
Izvedla je študije biološke enakovrednosti, s katerimi je dokazala, da 500-miligramski odmerek zdravila Cepecitabine Medac ustvarja enake ravni kapecitabina v krvi kot 500-miligramski odmerek zdravila Xeloda.
Capecitabine Medac should only be prescribed by a doctor who is qualified in the use of anticancer medicines.
Zdravilo Capecitabine Medac sme predpisati samo zdravnik, ki je usposobljen za uporabo zdravil proti raku.
Capecitabine Medac is a ‘generic' and a ‘hybrid' medicine.
Zdravilo Capecitabine Medac je „generično“ in „hibridno“ zdravilo.
The Committee recommended that Capecitabine Medac be given marketing authorisation.
Priporočil je, da se za zdravilo Capecitabine Medac odobri dovoljenje za promet.
Capecitabine Medac is used with docetaxel (another anticancer medicine) after treatment with anthracyclines (another type of anticancer medicine) has failed.
Zdravilo Capecitabine Medac se uporablja sočasno z docetakselom (drugim zdravilom proti raku), potem ko zdravljenje z antraciklini (drugo vrsto zdravil proti raku) ni bilo uspešno.
Capecitabine Medac is used with other anticancer medicines, including a platinum-containing anticancer medicine such as cisplatin;
Zdravilo Capecitabine Medac se uporablja skupaj z drugimi zdravili proti raku, vključno z zdravilom proti raku, ki vsebuje platino, kot na primer cisplatin;
Capecitabine Medac is an anticancer medicine.
Capecitabine Medac je zdravilo proti raku.
• advanced gastric (stomach) cancer.
• napredovale oblike raka želodca.
Capecitabine Medac is a medicine that contains the active substance capecitabine.
Capecitabine Medac je zdravilo, ki vsebuje zdravilno učinkovino kapecitabin.
The active substance in Capecitabine Medac, capecitabine, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group ‘anti-metabolites'.
Zdravilna učinkovina zdravila Capecitabine Medac, kapecitabin, je citotoksik (zdravilo, ki uniči celice v fazi delitve, kot na primer rakave celice) iz skupine antimetabolitov.
Capecitabine Medac is used with or without other anticancer medicines in patients who have had surgery for ‘stage III' or ‘Dukes' stage C' colon cancer;
Zdravilo Capecitabine Medac se uporablja sočasno z drugimi zdravili proti raku ali kot samostojno zdravilo pri bolnikih po operaciji raka kolona stadija III ali stadija Dukes C;
Why has Capecitabine Medac been approved?
Zakaj je bilo zdravilo Capecitabine Medac odobreno?
What is Capecitabine Medac?
Kaj je zdravilo Capecitabine Medac?
Capecitabine Medac is used with or without other anticancer medicines;
Zdravilo Capecitabine Medac se uporablja skupaj z drugimi zdravili proti raku ali kot samostojno zdravilo;
How has Capecitabine Medac been studied?
Kako je bilo zdravilo Capecitabine Medac raziskano?
How does Capecitabine Medac work?
Kako zdravilo Capecitabine Medac deluje?
What is Capecitabine Medac used for?
Za kaj se zdravilo Capecitabine Medac uporablja?
How is Capecitabine Medac used?
Kako se zdravilo Capecitabine Medac uporablja?
3 years.
3 leti.
frequency cannot be estimated from the available data.
pogostnosti iz razpoložljivih podatkov ni mogoče oceniti.
4.5 Interaction with other medicinal products and other forms of interaction
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
A change of therapy is recommended in this situation.
V tem položaju je priporočljiva sprememba zdravljenja.
In order to follow up your condition and treatment your doctor will check your blood and urine on a regular basis.
Da bi zdravnik lahko spremljal vaše stanje in zdravljenje, bo redno pregledoval vašo kri in urin.
Treatment of Wilson's disease.
Zdravljenje Wilsonove bolezni.
4.8 Undesirable effects
4.8 Neželeni učinki
It may harm them, even if their symptoms are the same as yours.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.
Uncommon: • A decrease in blood red and white cells may occur.
Občasni:: • Lahko pride do znižanja rdečih in belih krvničk.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines webportal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
• Children and adolescents:
• Otroci in mladostniki:
Please tell your doctor or your pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
Data are very limited in children under 6 years but since the disease is fully penetrant, prophylactic treatment should be considered as early as possible.
Pri otrocih, mlajših od 6 let, je na voljo zelo malo podatkov, ker pa je bolezen povsem penetrantna, je treba čimprej pretehtati možnost profilaktičnega zdravljenja.
Taking other medicines
Jemanje drugih zdravil
Hard capsule.
Trda kapsula.
The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.
Imetnik tega dovoljenja za promet z zdravilom mora obvestiti Evropsko Komisijo o načrtu trženja za zdravilo, odobreno s to odločbo.
A. LABELLING
A. OZNAČEVANJE
System organ class
Sistemski organski razred
Therapeutic monitoring
Terapevtsko spremljanje
You should tell your doctor if you experience unusual muscle weakness or abnormal feeling in your limbs as this may indicate excessive treatment.
Vašemu zdravniku morate povedati, če opazite nenavadno šibkost mišic ali neobičajne občutke v okončinah, ker lahko slednje kaže na pretirano zdravljenje.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Delaying the first dose to mid-morning or taking the dose with a little protein may usually relieve the symptoms.
Preložitev prvega odmerka na sredino dopoldneva ali jemanje odmerka z malo beljakovin navadno olajša simptome.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE
This is to ensure that you receive sufficient treatment.
S tem se bo prepričal, ali dobivate dovolj zdravila.
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
However, protein appears to interfere the least.
Zdi pa se, da absorpcijo še najmanj ovirajo beljakovine.
Frequencies are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Pogostost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10) občasni (≥ 1/1.000 do < 1/100), redki (1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Each bottle contains 250 capsules.
Vsaka plastenka vsebuje 250 kapsul.
Whether this is related to mobilisation of copper stores or to natural history of the disease remains unclear.
Ni jasno, ali je to povezano z mobilizacijo zalog bakra ali z naravnim potekom bolezni.
In the blood, about 80% of absorbed zinc is distributed to erythrocytes, with most of the remainder being bound to albumin and other plasma proteins.
V krvi se okrog 80 % absorbiranega cinka porazdeli v eritrocite, večina preostalega cinka pa se veže na albumine in druge plazemske beljakovine.
Anaemia may be micro-, normo- or macrocytic and is often associated with leukopenia.
Anemija je lahko mikrocitna, normocitna ali makrocitna in je pogosto povezana z levkopenijo.
Medicines should not be disposed of via wastewater or household waste.
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
• Changes in blood tests have been reported, including an increase in some liver and pancreatic enzymes.
• Poročajo o spremembah rezultatov preiskav krvi, med drugim o zvišanju nekaterih jetrnih encimov in encimov trebušne slinavke.
Do not take Wilzin If you are allergic (hypersensitive) to zinc or any of the other ingredients of Wilzin.
Ne jemljite zdravila Wilzin Če ste alergični (preobčutljivi) na cink ali katerokoli sestavino zdravila Wilzin.
If you take more Wilzin than you should:
Če ste vzeli večji odmerek zdravila Wilzin, kot bi smeli:
This is usually worst with the first morning dose and disappears after the first days of treatment.
Navadno so težave najhujše pri prvem jutranjem odmerku in po prvih dneh zdravljenja izginejo.
Wilson's disease will persist during the entire lifetime of the patient and therefore the need for this treatment is life-long.
Wilsonova bolezen traja vse bolnikovo življenje, zato je tudi zdravljenje potrebno vse življenje.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA OTROK
Some patients experience stomach upset after the morning dose.
Nekateri bolniki imajo po jutranjem odmerku želodčne težave.
If you become pregnant during therapy with Wilzin, your doctor will decide which treatment and which dose is best in your situation.
Če zanosite med zdravljenjem z Wilzinom, bo vaš zdravnik odločil, katero zdravilo in kakšen odmerek bosta za vas najboljša.
INFORMATION ON BRAILLE
PODATKI V BRAILLOVI PISAVI
WHAT WILZIN IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO WILZIN IN ZA KAJ GA UPORABLJAMO
Read the package leaflet before use.
Pred uporabo preberite priloženo navodilo.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
In this case, you must inform your doctor.
V tem primeru morate obvestiti zdravnika.
The same dose did not produce any symptoms except for vomiting in an adolescent who was treated by whole-bowel irrigation.
Enak odmerek ni povzročil nobenih simptomov razen bruhanja pri mladostniku, ki so ga zdravili z izpiranjem celotnega črevesja.
4.6 Pregnancy and lactation
4.6 Nosečnost in dojenje
It is extremely important that pregnant Wilson's disease patients continue their therapy during pregnancy.
Izredno pomembno je, da nosečnice z Wilsonovo boleznijo med nosečnostjo nadaljujejo z zdravljenjem.
Detailed information on this product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu
Wilzin treatment should be initiated under the supervision of a physician experienced in the treatment of Wilson's disease (see section 4.4).
Zdravljenje z Wilzinom se mora uvesti pod nadzorom zdravnika, ki je izkušen v zdravljenju Wilsonove bolezni (glejte poglavje 4.4).
Pharmacotherapeutic group: various alimentary tract and metabolism products, ATC code: A16AX05.
Farmakoterapevtska skupina: razna zdravila za bolezni prebavil in presnove, Oznaka ATC: A16AX05.
Which treatment should be used, zinc or chelating agent should be decided by the physician.
O tem, katero zdravilo naj se uporabi, cink ali kelator, naj odloči zdravnik.
For a full list of excipients, see section 6.1.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
The absorption of zinc may be reduced by iron and calcium supplements, tetracyclines and phosphorus-containing compounds, while zinc may reduce the absorption of iron, tetracyclines, fluoroquinolones.
Absorpcijo cinka lahko zmanjšajo dodatki železa in kalcija, tetraciklini in spojine, ki vsebujejo fosfor, medtem ko cink lahko zmanjša absorpcijo železa, tetraciklinov in fluorokinolonov.
Patients may present clinically with predominantly hepatic, neurologic, or psychiatric symptoms.
Bolniki lahko klinično kažejo prevladujoče jetrne, nevrološke ali psihiatrične simptome.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov izdelovalca, odgovornega za sprostitev zadevne serije.
• Pregnant women:
• Nosečnice:
Pharmacological and toxicological data available showed large similarities between zinc salts and among animal species.
Farmakološki in toksikološki podatki, ki so na voljo, kažejo veliko podobnost med posameznimi cinkovimi solmi in med različnimi živalskimi vrstami.
• Risk Management Plan (RMP)
• Načrt za obvladovanje tveganj (RMP) Navedba smiselno ni potrebna.
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Izdaja zdravila je le pod omejenimi pogoji in na recept (glejte Dodatek I: Povzetek glavnih značilnosti zdravila, poglavje 4.2)
These side effects may occur with certain frequencies, which are defined as follows: • very common:
Do neželenih učinkov lahko pride z določeno pogostostjo, ki je definirana na naslednji način:
Dietary copper, which cannot be properly eliminated, accumulates first in the liver, then in other organs such as the eyes and the brain.
Baker iz hrane, ki se ne more pravilno odstraniti iz telesa, se kopiči najprej v jetrih, nato v drugih organih, na primer v očeh in možganih.
Dietary fibres and some dairy products, in particular, delay the absorption of zinc salts.
Posebno vlaknine v hrani in nekateri mlečni izdelki odložijo absorpcijo cinkovih soli.
This is probably due to some extent of complexion of zinc by the chelator, thus reducing the effect of both active substances.
To je do neke mere verjetno posledica vezave cinka s kelatorjem, s čimer se zmanjša učinek obeh zdravilnih učinkovin.
4.7 Effects on ability to drive and use machines
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji
• After Wilzin intake, gastric irritation may occur, especially at the beginning of treatment.
• Po vzetju Wilzina se lahko pojavi draženje želodca, posebno v začetku zdravljenja.
As with other anti-copper agents such as penicillamine, your symptoms may get worse after starting the treatment.
Tako kot pri drugih sredstvih proti bakru, na primer pri penicilaminu, se lahko vaši simptomi po začetku zdravljenja poslabšajo.
Studies of the co-administration of zinc with food performed in healthy volunteers showed that the absorption of zinc was significantly delayed by many foods (including bread, hard boiled eggs, coffee and milk).
Študije sočasnega jemanja cinka s hrano, opravljene na zdravih prostovoljcih, so pokazale, da so absorpcijo cinka pomembno upočasnile številne vrste hrane (med drugim kruh, trdo kuhana jajca, kava in mleko).
Substances in food, especially phytates and fibres, bind zinc and prevent it from entering the intestinal cells.
Snovi v hrani, posebno fitati in vlaknine, vežejo cink in mu preprečujejo vstop v črevesne celice.
Bone marrow examination usually reveals characteristic "ringed sideroblasts" (i.e. developing red blood cells containing iron-engorged paranuclear mitochondria).
Preiskava kostnega mozga navadno pokaže značilne “obročaste sideroblaste” (t.j., razvijajoče se rdeče krvničke, ki vsebujejo z železom nabite paranuklearne mitohondrije).
Although rare, clinical deterioration may occur at the beginning of the treatment, as has also been reported with chelating agents.
Čeprav je klinično poslabšanje redko, se lahko pojavi v začetku zdravljenja, kot poročajo tudi za kelatorje.
If the morning dose is not well tolerated (see section 4) it is possible to delay it to mid-morning, between breakfast and lunch.
Če jutranjega odmerka ne prenašate dobro (glejte poglavje 4), ga lahko odložite na sredino dopoldneva, med zajtrkom in kosilom.
Like with all anti-copper agents overtreatment carries the risk of copper deficiency, which is especially harmful for children and pregnant women since copper is required for proper growth and mental development.
Podobno kot pri vseh sredstvih proti bakru preveč intenzivno zdravljenje prinaša nevarnost pomanjkanja bakra, ki je še posebno škodljiva za otroke in nosečnice, ker je baker potreben za pravilno rast in duševni razvoj.
Elevations of serum alkaline phosphatase, amylase and lipase may occur after a few weeks of treatment, with levels usually returning to high normal within the first one or two years of treatment.
Po nekaj tednih zdravljenja se lahko pojavi zvišanje serumske alkalne fosfataze, amilaze in lipaze, koncentracije se navadno vrnejo v območje visokih normalnih vrednosti po enem do dveh letih zdravljenja.